Earnings rise in Q1 2026 at Pediatrix Medical Group (NYSE: MD)
Rhea-AI Filing Summary
Pediatrix Medical Group reported stronger first quarter 2026 results, with net revenue of $476.2 million for the three months ended March 31, 2026, up from $458.4 million a year earlier. Earnings were $0.36 per diluted share, and Adjusted EPS, which excludes items such as amortization, stock-based compensation and transformational and restructuring expenses, was $0.44.
Net income was $30 million and Adjusted EBITDA reached $58 million. Same-unit revenue grew 2.8 percent, driven mainly by a 4.4 percent increase in same-unit revenue from net reimbursement-related factors, reflecting better cash collections, higher hospital contract administrative fees, higher patient acuity and a slightly favorable payor mix. Same-unit patient volume declined by 1.6 percent.
As of March 31, 2026, Pediatrix reported cash and cash equivalents of $205.8 million, total debt of $590.8 million and total shareholders’ equity of $878.6 million.
Positive
- Stronger profitability on modest revenue growth: Q1 2026 diluted EPS rose to $0.36 and Adjusted EPS to $0.44, while Adjusted EBITDA increased to $58 million from $49 million, reflecting operating leverage and improved reimbursement-related revenue.
Negative
- None.
Insights
Pediatrix posted modest revenue growth but much stronger earnings and EBITDA in Q1 2026.
Pediatrix Medical Group increased net revenue to $476.2 million from $458.4 million for Q1, helped by 2.8 percent same-unit revenue growth. Profitability improved more sharply, with net income of $30 million and Adjusted EBITDA of $58 million, up from $49 million.
Drivers were a 4.4 percent rise in same-unit revenue from reimbursement factors, reflecting improved collections, higher hospital contract administrative fees, higher patient acuity and a slightly better payor mix, while same-unit volumes fell 1.6 percent. Diluted EPS rose to $0.36 and Adjusted EPS to $0.44, versus $0.24 and $0.33 a year earlier, indicating operating leverage despite modest top-line growth.
The balance sheet shows cash and cash equivalents of $205.8 million, total debt of $590.8 million and shareholders’ equity of $878.6 million as of March 31, 2026. The company also presents a 2026 range for net income and Adjusted EBITDA, but comparisons to prior guidance are not provided in this excerpt.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
Adjusted EPS financial
same-unit revenue financial
payor mix financial
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 5, 2026, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months ended March 31, 2026 (the “First Quarter Release”). A copy of the First Quarter Release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” with the Securities and Exchange Commission nor incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
Exhibit Index
99.1— Press Release of Pediatrix Medical Group, Inc. dated May 5, 2026.
104 — Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Pediatrix Medical Group, Inc. |
|
|
|
|
Date: |
May 5, 2026 |
By: |
/s/ Kasandra H. Rossi |
|
|
|
Kasandra H. Rossi |
FOR MORE INFORMATION:
Kasandra H. Rossi
Executive Vice President, Chief Financial Officer & Treasurer
954-692-7163
kasandra.rossi@pediatrix.com
FOR IMMEDIATE RELEASE
Pediatrix Medical Group Reports First Quarter Results
FORT LAUDERDALE, Fla., May 5, 2026 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44.
For the 2026 first quarter, Pediatrix reported the following results:
“Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. “Our priorities for 2026 remain focused on maximizing quality driven support for our hospital partners. With robust cash flow and a healthy balance sheet, we believe we are also well-positioned to find new opportunities and move decisively.”
Operating Results– Three Months Ended March 31, 2026
Pediatrix’s net revenue for the three months ended March 31, 2026 was $476.2 million, compared to $458.4 million for the prior-year period. This increase reflects growth in same-unit revenue of 2.8 percent, and to a lesser extent, growth in non-same unit activity, driven by recent acquisitions, partially offset by practice dispositions.
Same-unit revenue from net reimbursement-related factors increased by 4.4 percent for the 2026 first quarter as compared to the prior-year period. This increase primarily reflects improved cash collections, an increase in hospital contract administrative fees, higher patient acuity, primarily in neonatology, and a slightly favorable shift in payor mix. The percentage of services reimbursed by commercial and other non-government payors increased by 45 basis points compared to the prior-year period.
Same-unit revenue attributable to patient volume decreased by 1.6 percent for the 2026 first quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months ended March 31, 2026. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)
|
|
Three Months Ended |
Hospital-based patient services |
|
(1.5)% |
Office-based patient services |
|
(3.3)% |
|
|
|
Neonatology services (within hospital-based services): |
|
|
Neonatal intensive care unit (NICU) days |
|
(0.8)% |
For the 2026 first quarter, practice salaries and benefits expense was $345.7 million, compared to $337.0 million for the prior-year period. This increase primarily reflects increases in same-unit clinical salaries expense.
For the 2026 first quarter, general and administrative expenses were $60.3 million, as compared to $58.6 million for the prior-year period. This increase primarily reflects an increase in incentive compensation expense based on financial results, partially offset by decreases in certain professional services and other expenses.
For the 2026 first quarter, transformational and restructuring related expenses were $4.9 million, compared to $6.6 million for the prior-year period. The expenses in both periods were related to revenue cycle management transition activities and position eliminations.
Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization and transformational and restructuring related expenses, was $58.2 million for the 2026 first quarter, compared to $49.2 million for the prior-year period. The increase in Adjusted EBITDA was primarily due to net favorable impacts from same-unit results and recent acquisitions.
Depreciation and amortization expense was $6.1 million for the first quarter of 2026, compared to $5.3 million for the same period in 2025. The increase was primarily related to capital expenditures at our existing units and from amortization of intangible assets and capital expenditures from recent acquisitions.
Interest expense was $8.3 million for the first quarter of 2026, compared to $9.2 million for the first quarter of 2025, reflecting a reduction in interest expense from modestly lower interest rates and borrowings.
Investment and other income was $4.8 million for the first quarter of 2026, compared to $4.7 million for the prior-year period.
2
Pediatrix generated net income of $29.6 million, or $0.36 per diluted share, for the 2026 first quarter, based on a weighted average shares outstanding of 83.1 million. This compares with net income of $20.7 million, or $0.24 per diluted share, for the 2025 first quarter, based on a weighted average shares outstanding of 85.4 million. The decrease in our weighted average shares outstanding is primarily due to the impact of shares repurchased under our repurchase program, partially offset by issuances of restricted stock.
For the first quarter of 2026, Pediatrix reported Adjusted EPS of $0.44, compared to $0.33 for the first quarter of 2025. For these periods, Adjusted EPS is defined as diluted income per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, and impacts from discrete tax events.
Financial Position and Cash Flow – Continuing Operations
Pediatrix had cash and cash equivalents of $205.8 million at March 31, 2026, compared to $375.2 million at December 31, 2025, and net accounts receivable at March 31, 2026 were $224.8 million.
For the first quarter of 2026, Pediatrix used cash of $129.5 million to fund continuing operations, compared to a use of $116.1 million during the first quarter of 2025. Pediatrix typically uses cash during the first quarter of each year as it pays incentive compensation, primarily to its affiliated physicians, and makes employee benefit plan matching contributions that were accrued during the prior year. Additionally, during the first quarter of 2026, the Company used $21.5 million to fund share repurchases, $7.0 million to fund acquisitions and $6.2 million to fund capital expenditures.
At March 31, 2026, Pediatrix had total debt outstanding of $591 million, consisting of its $400 million in 5.375% Senior Notes due 2030 and $191 million in borrowings under its Term A Loan. At March 31, 2026, the Company had no outstanding borrowings under its $450 million revolving line of credit.
2026 Outlook
Pediatrix reaffirms its full year 2026 outlook for Adjusted EBITDA, as defined above, and anticipates Adjusted EBITDA will be in a range of $280 million to $300 million.
Non-GAAP Measures
A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three months ended March 31, 2026 and 2025 is provided in the financial tables of this press release. A reconciliation of projected full year 2026 Adjusted EBITDA to the most directly comparable GAAP financial measures is provided in the financial tables of this press release.
Earnings Conference Call
3
Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.pediatrix.com. A replay of the conference call will also be available at www.pediatrix.com.
ABOUT PEDIATRIX MEDICAL GROUP
Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.
Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, its full year 2026 guidance, future impacts of legal, regulatory, political and macroeconomic developments and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the effects of economic conditions on the Company’s business; the effects of the Medicare Access and CHIP Reauthorization Act of 2015, the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors; the impact of state
4
budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company’s transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company’s ability to comply with the terms of debt financing arrangements and the Company’s ability to replace, refinance or extend its current debt financing arrangements; and the effects of the Company’s transformation initiatives, including our renewed focus, and growth strategy for, the Company’s hospital-based and maternal-fetal service lines.
###
5
Pediatrix Medical Group, Inc.
Consolidated Statements of Income and Comprehensive Income
(in thousands, except per share data)
(Unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Net revenue |
|
$ |
476,196 |
|
|
$ |
458,359 |
|
Operating expenses: |
|
|
|
|
|
|
||
Practice salaries and benefits |
|
|
345,744 |
|
|
|
337,031 |
|
Practice supplies and other operating expenses |
|
|
17,488 |
|
|
|
18,686 |
|
General and administrative expenses |
|
|
60,266 |
|
|
|
58,604 |
|
Depreciation and amortization |
|
|
6,119 |
|
|
|
5,332 |
|
Transformational and restructuring related expenses |
|
|
4,922 |
|
|
|
6,605 |
|
Total operating expenses |
|
|
434,539 |
|
|
|
426,258 |
|
Income from operations |
|
|
41,657 |
|
|
|
32,101 |
|
Investment and other income |
|
|
4,760 |
|
|
|
4,737 |
|
Interest expense |
|
|
(8,265 |
) |
|
|
(9,154 |
) |
Equity in earnings of unconsolidated affiliate |
|
|
692 |
|
|
|
406 |
|
Total non-operating expenses |
|
|
(2,813 |
) |
|
|
(4,011 |
) |
Income before income taxes |
|
|
38,844 |
|
|
|
28,090 |
|
Income tax provision |
|
|
(9,272 |
) |
|
|
(7,353 |
) |
Net income |
|
$ |
29,572 |
|
|
$ |
20,737 |
|
Other comprehensive income, net of tax |
|
|
|
|
|
|
||
Unrealized holding (loss) gain on investments, net of tax of $152 and $255 |
|
|
(533 |
) |
|
|
779 |
|
Total comprehensive income |
|
$ |
29,039 |
|
|
$ |
21,516 |
|
Per common and common equivalent share data (diluted): |
|
|
|
|
|
|
||
Net income: |
|
$ |
0.36 |
|
|
$ |
0.24 |
|
Weighted average common shares |
|
|
83,075 |
|
|
|
85,430 |
|
6
Pediatrix Medical Group, Inc.
Reconciliation of Net Income to Adjusted EBITDA
(in thousands)
(Unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Net income |
|
$ |
29,572 |
|
|
$ |
20,737 |
|
Interest expense |
|
|
8,265 |
|
|
|
9,154 |
|
Income tax provision |
|
|
9,272 |
|
|
|
7,353 |
|
Depreciation and amortization expense |
|
|
6,119 |
|
|
|
5,332 |
|
Transformational and restructuring related expenses |
|
|
4,922 |
|
|
|
6,605 |
|
Adjusted EBITDA |
|
$ |
58,150 |
|
|
$ |
49,181 |
|
7
Pediatrix Medical Group, Inc.
Reconciliation of Diluted Net Income per Share
to Adjusted Income per Diluted Share (“Adjusted EPS”)
(in thousands, except per share data)
(Unaudited)
|
|
Three Months Ended |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
||||||||||
Weighted average diluted shares outstanding |
|
83,075 |
|
|
85,430 |
|
||||||||||
Net income and diluted net income per share |
|
$ |
29,572 |
|
|
$ |
0.36 |
|
|
$ |
20,737 |
|
|
$ |
0.24 |
|
Adjustments (1): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization (net of tax of $564 and $430) |
|
|
1,695 |
|
|
|
0.02 |
|
|
|
1,290 |
|
|
|
0.01 |
|
Stock-based compensation (net of tax of $937 and $573) |
|
|
2,808 |
|
|
|
0.03 |
|
|
|
1,720 |
|
|
|
0.02 |
|
Transformational and restructuring expenses (net of tax of $1,230 and $1,651) |
|
|
3,692 |
|
|
|
0.04 |
|
|
|
4,954 |
|
|
|
0.06 |
|
Net impact from discrete tax events |
|
|
(1,135 |
) |
|
|
(0.01 |
) |
|
|
(175 |
) |
|
|
— |
|
Adjusted income and diluted EPS |
|
$ |
36,632 |
|
|
$ |
0.44 |
|
|
$ |
28,526 |
|
|
$ |
0.33 |
|
8
Pediatrix Medical Group, Inc.
Balance Sheet Highlights
(in thousands)
(Unaudited)
|
|
As of |
|
|
As of |
|
||
Assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
205,780 |
|
|
$ |
375,241 |
|
Short-term investments |
|
|
123,194 |
|
|
|
124,482 |
|
Accounts receivable, net |
|
|
224,801 |
|
|
|
229,665 |
|
Other current assets |
|
|
33,259 |
|
|
|
34,126 |
|
Intangible assets, net |
|
|
15,937 |
|
|
|
16,862 |
|
Operating and finance lease right-of-use assets |
|
|
36,871 |
|
|
|
34,330 |
|
Goodwill, other assets, property and equipment |
|
|
1,430,453 |
|
|
|
1,431,990 |
|
Total assets |
|
$ |
2,070,295 |
|
|
$ |
2,246,696 |
|
Liabilities and shareholders' equity: |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
236,930 |
|
|
$ |
419,530 |
|
Total debt, including finance leases, net |
|
|
590,769 |
|
|
|
597,338 |
|
Operating lease liabilities |
|
|
38,946 |
|
|
|
37,277 |
|
Other liabilities |
|
|
325,074 |
|
|
|
326,697 |
|
Total liabilities |
|
|
1,191,719 |
|
|
|
1,380,842 |
|
Total shareholders' equity |
|
|
878,576 |
|
|
|
865,854 |
|
Total liabilities and shareholders' equity |
|
$ |
2,070,295 |
|
|
$ |
2,246,696 |
|
9
Pediatrix Medical Group, Inc.
Reconciliation of Net Income to Forward-Looking Adjusted EBITDA
(in thousands)
(Unaudited)
|
|
Year Ended |
|
|||||
|
|
|
|
|
|
|
||
Net income |
|
$ |
152,100 |
|
|
$ |
166,700 |
|
Interest expense |
|
|
33,500 |
|
|
|
33,500 |
|
Income tax provision |
|
|
56,300 |
|
|
|
61,700 |
|
Depreciation and amortization expense |
|
|
24,800 |
|
|
|
24,800 |
|
Transformational and restructuring related expenses |
|
|
13,300 |
|
|
|
13,300 |
|
Adjusted EBITDA |
|
$ |
280,000 |
|
|
$ |
300,000 |
|
10